[Ambulatory coronary arteriography].

Based upon hospital files and a questionnaire we assessed the patient safety of and the patient attitude towards outpatient coronary angiography (CAG). A total of 115 consecutive patients were included in the study. Thirty two of the patients (28%) were admitted following the angiography, while 83 (72%) were discharged to the home as planned.

[Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily].

Forty patients with stable asthma and daily need for inhaled beta 2-agonist, were included in a randomized double-blind study. They were treated for six weeks with inhaled beta 2-agonist, either salbutamol, 4 x 200 micrograms daily, of formoterol, 2 x 12 micrograms and 2 x placebo daily. This was preceded by a run-in period, where all patients received terbutalin-inhalation, 4 x 500 micrograms daily.

Drug-related illness as a cause of admission to a department of respiratory medicine.

Three hundred and thirteen consecutive admissions to a department of respiratory medicine were evaluated in a prospective high-intensity monitoring scheme concerning adverse drug reactions or dose-related therapeutic failures as the contributing or sole cause of hospital admission. Eleven patients [3.5%, 95% confidence interval (CI) 2.

Cellular targets and receptors for interleukin-6. II. Characterization of IL-6 binding and receptors in peripheral blood cells and macrophages.

Within 15 min, approximately 2.5% of 125I-labelled interleukin-6 (IL-6) injected intravenously into rats was taken up by the spleen. As determined by light microscopic autoradiography, uptake was mainly (60%) accounted for by macrophages in the red pulp.

Cellular targets and receptors for interleukin-6. I. In vivo and in vitro uptake of IL-6 in liver and hepatocytes.

Interleukin-6 (IL-6) is a potent stimulator of the hepatic synthesis of acute-phase proteins. 125I-labelled IL-6 disappeared from the blood of rats with an overall half-time of about 1.5 min; 41% of the injected tracer dose was recovered in the liver by 15 min.